Skip to main content
. 2014 Aug 4;35(9):1188–1198. doi: 10.1038/aps.2014.65

Figure 5.

Figure 5

The impact of NAC or mangiferin on TA3-induced hepatotoxicity in SCRHs. (A) The ROS level was measured after TA3 (5 and 10 μmol/L) treatment for 8 h. (B) Real-time PCR analysis of HO-1 expression in hepatocytes treated with TA3 (1, 5, and 10 μmol/L) for 24 h. Cells were pretreated with NAC (5 mmol/L) and co-incubated with TA3 (1, 5, 10, and 20 μmol/L), then the ROS level (C) and ATP level (D) was measured. (E) The ROS level after pretreatment with mangiferin (10, 50, and 200 μg/mL) and NAC (5 mmol/L) for 2 h and co-incubated with TA3 (10 μmol/L) for 24 h. (F) The MMP level after pretreatment with NAC (5 mmol/L) for 2 h and co-incubation with TA3 (10 μmol/L) for 12 h. CCCP (20 μmol/L) was used as a positive control. The data are presented as the mean±SD (n=5). bP<0.05, cP<0.01 compared with the control. eP<0.05, fP<0.01 (TA3+NAC/mangiferin treatment vs TA3 alone).